Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK Stok Raporu

Piyasa değeri: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Paratek Pharmaceuticals CEO'su Evan Loh, Jun2019 tarihinde atandı, in görev süresi 4.25 yıldır. in toplam yıllık tazminatı $ 2.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 31.8% maaş ve 68.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.87% ine doğrudan sahiptir ve bu hisseler $ 2.38M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 8.9 yıldır.

Anahtar bilgiler

Evan Loh

İcra Kurulu Başkanı

US$2.0m

Toplam tazminat

CEO maaş yüzdesi31.82%
CEO görev süresi4.3yrs
CEO sahipliği1.9%
Yönetim ortalama görev süresi4.3yrs
Yönetim Kurulu ortalama görev süresi8.9yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Apr 17

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shares have had a really impressive month, gaining 77% after a shaky...
Seeking Alpha • Aug 24

Paratek Pharmaceuticals: Patience Is Wearing Thin

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst support. What lies ahead for Paratek? An investment analysis follows in the paragraphs below. If you must speak ill of another, do not speak it, write it in the sand near the water's edge. ― Napoleon Hill Today, we are circling back on Paratek Pharmaceuticals (PRTK) for the first time since we posted this piece on this small antibiotic concern back in October of last year. Even as the company has demonstrated solid revenue growth, shareholders have not been rewarded in this name over the past year and patience is starting to wear thin. We update our investment thesis around Paratek Pharmaceuticals via the analysis below. Seeking Alpha Company Overview Paratek Pharmaceuticals is a Boston based antibiotic concern. The company's primary asset is NUZYRA. This is a once-daily oral and intravenous broad-spectrum antibiotic approved for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. The stock sells for around $2.75 a share and sports an approximate market cap of just under $150 million. August Company Presentation The company has some earlier stage candidates in its pipeline. None of them of note to this analysis given they are early in development. The company is advancing NUZYRA in Phase 2 development for Non-Tuberculous Mycobacteria or NTM for which it has Orphan Drug and Fast Track designations from the FDA. August Company Presentation Second Quarter Results On August 3rd, the company posted second quarter numbers. Paratek posted a GAAP loss of 33 cents a share, just a tad above the consensus. Net revenue for the second quarter of 2022 was $29.6 million. This compares to $19.6 million in 2Q2021 when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million (more detail on that contract in the last section of this article). August Company Presentation The $29.6 million in sales for the quarter included $25.1 million of revenues from NUZYRA's core commercial business. This was up from $14.9 million from the same period a year ago. The company also booked $4 million in sales from the BARDA contract and $600,000 in royalty revenue from SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. August Company Presentation Analyst Commentary & Balance Sheet Only three analyst firms have chimed in around Paratek so far in 2022. On February 10th, WBB Securities upgraded the shares to a Strong Buy with a $11 price target as the analyst there believes 'Nuzyra is a critically important antibiotic that has anchored the franchise'. This month BTIG ($30 price target) and H.C. Wainwright ($20 price target) both maintained their Buy ratings on the stock. Just under 10% of the outstanding float is currently held short. Four insiders sold just over $300,000 worth of shares collectively in August. That has been the only insider activity in the equity so far in 2022. The company ended the first half of this year with nearly $70 million in cash and marketable securities on its balance sheet. Management stated within its second quarter earnings press release that: Based upon the company's current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4 million as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even. August Company Presentation Verdict The current analyst consensus has the company losing a bit over 80 cents a share in FY2022 as revenues rise in the mid teens to some $150 million. Projections from three analyst firms that have provided estimates for FY2023 are in wide range both for earnings (A 42 cent a share loss to profits of $1.37 a share) and revenues ($195 million to $315 million).
Seeking Alpha • Aug 03

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q2 GAAP EPS of -$0.33 beats by $0.01. Revenue of $29.6M (-48.5% Y/Y) beats by $0.42M. Based upon the company’s current operating plan, Paratek anticipates its existing cash, cash equivalents and marketable securities of $69.4M as of June 30, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
Seeking Alpha • Jan 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

2021 revenue estimate: $128-139 million; 2022 revenue estimate: $200 million. Revenue estimates for CABP and ABSSSI near $400 million by 2028; NTM could generate even higher sales well into the 2030s. $304 million BARDA contract (2019-2023) provides a pathway to profitability by 4Q2022. Deeply undervalued: enterprise value of $369 million is less than 2X 2022 sales.
Seeking Alpha • Oct 18

The Play On Paratek Pharmaceuticals

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.
Seeking Alpha • Aug 07

Peeking Back In On Paratek Pharmaceuticals

The stock of Paratek Pharmaceuticals has fallen since we last took an in-depth look at this antibiotic company in March. Most of this is due to weakness in the sector. The company continues to make solid progress, and its shares are far below analyst firm price targets. A full and independent investment analysis follows in the paragraphs below.
Analiz Makalesi • Mar 01

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
Analiz Makalesi • Feb 01

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) can tell us which group is most powerful...

CEO Tazminat Analizi

Evan Loh'un ücretlendirmesi Paratek Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$650k

-US$64m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$86m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$4mUS$600k

-US$59m

Sep 30 2021n/an/a

-US$52m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$2mUS$575k

-US$97m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$111m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$2mUS$520k

-US$129m

Sep 30 2019n/an/a

-US$124m

Jun 30 2019n/an/a

-US$124m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$2mUS$480k

-US$112m

Sep 30 2018n/an/a

-US$111m

Jun 30 2018n/an/a

-US$101m

Mar 31 2018n/an/a

-US$89m

Dec 31 2017US$3mUS$450k

-US$89m

Sep 30 2017n/an/a

-US$94m

Jun 30 2017n/an/a

-US$96m

Mar 31 2017n/an/a

-US$108m

Dec 31 2016US$1mUS$415k

-US$112m

Tazminat ve Piyasa: Evan 'nin toplam tazminatı ($USD 2.04M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 630.36K ).

Tazminat ve Kazançlar: Evan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Evan Loh (64 yo)

4.3yrs
Görev süresi
US$2,042,511
Tazminat

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director4.3yrsUS$2.04m1.87%
$ 2.4m
Adam Woodrow
President & Chief Commercial Officer4.3yrsUS$1.15m1.09%
$ 1.4m
Sarah Higgins
VP of Finance8.5yrsVeri yokVeri yok
William Haskel
Senior VP8.3yrsUS$1.25m0.62%
$ 797.8k
Jonathan Light
Deputy General Counsel & Chief Compliance Officer6.1yrsVeri yokVeri yok
Karen McGrath
Chief People Officer4.2yrsVeri yokVeri yok
Randall Brenner
Chief Development & Regulatory Officer4.3yrsVeri yok0.58%
$ 735.2k
4.3yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş

Deneyimli Yönetim: PRTK 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director11.3yrsUS$2.04m1.87%
$ 2.4m
Jeffrey Stein
Lead Independent Director8.9yrsUS$147.80k0.097%
$ 124.0k
Thomas Dietz
Independent Outside Director8.9yrsUS$150.30k0.087%
$ 111.5k
Kristine Peterson
Independent Outside Director7.5yrsUS$137.80k0.10%
$ 131.6k
Timothy Franson
Independent Outside Director8.2yrsUS$135.30k0.10%
$ 131.6k
Robert Radie
Independent Outside Director8.9yrsUS$140.30k0.091%
$ 116.5k
Rolf Hoffmann
Independent Director5.4yrsUS$127.80k0.11%
$ 142.7k
Minnie Baylor-Henry
Independent Director2.3yrsUS$132.80k0.068%
$ 87.4k
8.9yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: PRTK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2023/09/22 02:41
Gün Sonu Hisse Fiyatı2023/09/20 00:00
Kazançlar2023/06/30
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Paratek Pharmaceuticals, Inc. 11 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Michael UlzBaird
Jason Matthew GerberryBofA Global Research
Timothy ChiangBTIG